Form 4: Bionano Genomics Chief Medical Officer Reports Routine Stock Withholding for Tax Obligations

Bionano Genomics' Chief Medical Officer, Alka Chaubey, reported a routine disposition of 24 shares of common stock to cover tax withholding obligations related to the vesting of a restricted stock unit award.

Summary

• Alka Chaubey, Chief Medical Officer of Bionano Genomics, Inc. (BNGO), reported a transaction on June 3, 2025.
• The transaction involved the disposition of 24 shares of Bionano Genomics common stock at a price of $3.69 per share.
• This disposition was a withholding by the Issuer to satisfy tax withholding obligations upon the settlement of a Restricted Stock Unit (RSU) award.
• The RSU award was granted on June 3, 2024, and vested on June 3, 2025.
• Following this transaction, Alka Chaubey beneficially owns 713 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine administrative event (tax withholding on RSU vesting) and does not indicate a voluntary sale or purchase by the insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation and tax obligations, which is common across all industries for publicly traded companies and does not reflect broader industry trends.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, small-scale transaction for tax purposes, not a significant open-market sale or purchase.

Key Dates

Keywords

Bionano Genomics, BNGO, Form 4, Insider Transaction, Alka Chaubey, Chief Medical Officer, Restricted Stock Units, RSU, Tax Withholding, Equity Compensation